The global market for Persistent Epithelial Defect Management was valued at US$ 4612 million in the year 2024 and is projected to reach a revised size of US$ 10251 million by 2031, growing at a CAGR of 12.2% during the forecast period.

Persistent Epithelial Defect Management Market

With the global aging population and the increasing prevalence of chronic diseases such as diabetes and hypertension, the incidence of PED is rising. Advancements in diagnostic technologies and increased patient awareness have enabled early detection and intervention. Innovations in biologic therapies, stem cell treatments, and regenerative medicine are providing new avenues for PED management.

Despite advancements, PED treatment faces challenges such as high costs and limited accessibility. Therapies like amniotic membrane transplantation and autologous serum eye drops are effective but expensive and may not be readily available in all regions. Additionally, the variability in treatment responses among patients necessitates personalized treatment approaches, which require further research and development.

Patients are increasingly seeking treatments that not only restore vision but also ensure safety and comfort. Non-invasive therapies with minimal side effects, such as ocular biologics and stem cell-based treatments, are gaining popularity. Healthcare providers are focusing on personalized treatment plans to cater to individual patient needs, enhancing therapeutic outcomes and patient satisfaction.

The primary raw materials for PED treatment include amniotic membrane, stem cells, and recombinant growth factors. Amniotic membrane, a biological material, possesses excellent biocompatibility and promotes tissue repair, making it widely used in PED treatment. Stem cells, particularly mesenchymal stem cells, have self-renewal and multi-directional differentiation capabilities, serving as crucial components in PED therapy. Recombinant growth factors, such as recombinant nerve growth factor (rhNGF), play a significant role in promoting the proliferation and migration of corneal epithelial cells.

This report aims to provide a comprehensive presentation of the global market for Persistent Epithelial Defect Management, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Persistent Epithelial Defect Management.

The Persistent Epithelial Defect Management market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Persistent Epithelial Defect Management market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Persistent Epithelial Defect Management companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Persistent Epithelial Defect Management Market Report

Report Metric	Details
Report Name	Persistent Epithelial Defect Management Market
Accounted market size in year	US$ 4612 million
Forecasted market size in 2031	US$ 10251 million
CAGR	12.2%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Medication Physical Therapy Surgery Other
Segment by Application	Epithelial/Limbal Inflammatory Disease Neurotrophic Disease Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Dompe Farmaceutici, OcuNexus Therapeutics, Eyevance Pharmaceuticals, Noveome Biotherapeutics, RegeneRx Biopharmaceuticals, Recordati Rare Diseases, Mimetech, Johnson & Johnson, Bausch Health, Integra Lifesciences
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Persistent Epithelial Defect Management company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Persistent Epithelial Defect Management Market growing?

Ans: The Persistent Epithelial Defect Management Market witnessing a CAGR of 12.2% during the forecast period 2025-2031.

What is the Persistent Epithelial Defect Management Market size in 2031?

Ans: The Persistent Epithelial Defect Management Market size in 2031 will be US$ 10251 million.

Who are the main players in the Persistent Epithelial Defect Management Market report?

Ans: The main players in the Persistent Epithelial Defect Management Market are Dompe Farmaceutici, OcuNexus Therapeutics, Eyevance Pharmaceuticals, Noveome Biotherapeutics, RegeneRx Biopharmaceuticals, Recordati Rare Diseases, Mimetech, Johnson & Johnson, Bausch Health, Integra Lifesciences

What are the Application segmentation covered in the Persistent Epithelial Defect Management Market report?

Ans: The Applications covered in the Persistent Epithelial Defect Management Market report are Epithelial/Limbal, Inflammatory Disease, Neurotrophic Disease, Others

What are the Type segmentation covered in the Persistent Epithelial Defect Management Market report?

Ans: The Types covered in the Persistent Epithelial Defect Management Market report are Medication, Physical Therapy, Surgery, Other

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Persistent Epithelial Defect Management Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Medication

1.2.3 Physical Therapy

1.2.4 Surgery

1.2.5 Other

1.3 Market by Application

1.3.1 Global Persistent Epithelial Defect Management Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Epithelial/Limbal

1.3.3 Inflammatory Disease

1.3.4 Neurotrophic Disease

1.3.5 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Persistent Epithelial Defect Management Market Perspective (2020-2031)

2.2 Global Persistent Epithelial Defect Management Growth Trends by Region

2.2.1 Global Persistent Epithelial Defect Management Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Persistent Epithelial Defect Management Historic Market Size by Region (2020-2025)

2.2.3 Persistent Epithelial Defect Management Forecasted Market Size by Region (2026-2031)

2.3 Persistent Epithelial Defect Management Market Dynamics

2.3.1 Persistent Epithelial Defect Management Industry Trends

2.3.2 Persistent Epithelial Defect Management Market Drivers

2.3.3 Persistent Epithelial Defect Management Market Challenges

2.3.4 Persistent Epithelial Defect Management Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Persistent Epithelial Defect Management Players by Revenue

3.1.1 Global Top Persistent Epithelial Defect Management Players by Revenue (2020-2025)

3.1.2 Global Persistent Epithelial Defect Management Revenue Market Share by Players (2020-2025)

3.2 Global Top Persistent Epithelial Defect Management Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Persistent Epithelial Defect Management Revenue

3.4 Global Persistent Epithelial Defect Management Market Concentration Ratio

3.4.1 Global Persistent Epithelial Defect Management Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Persistent Epithelial Defect Management Revenue in 2024

3.5 Global Key Players of Persistent Epithelial Defect Management Head office and Area Served

3.6 Global Key Players of Persistent Epithelial Defect Management, Product and Application

3.7 Global Key Players of Persistent Epithelial Defect Management, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Persistent Epithelial Defect Management Breakdown Data by Type

4.1 Global Persistent Epithelial Defect Management Historic Market Size by Type (2020-2025)

4.2 Global Persistent Epithelial Defect Management Forecasted Market Size by Type (2026-2031)

5 Persistent Epithelial Defect Management Breakdown Data by Application

5.1 Global Persistent Epithelial Defect Management Historic Market Size by Application (2020-2025)

5.2 Global Persistent Epithelial Defect Management Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Persistent Epithelial Defect Management Market Size (2020-2031)

6.2 North America Persistent Epithelial Defect Management Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Persistent Epithelial Defect Management Market Size by Country (2020-2025)

6.4 North America Persistent Epithelial Defect Management Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Persistent Epithelial Defect Management Market Size (2020-2031)

7.2 Europe Persistent Epithelial Defect Management Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Persistent Epithelial Defect Management Market Size by Country (2020-2025)

7.4 Europe Persistent Epithelial Defect Management Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Persistent Epithelial Defect Management Market Size (2020-2031)

8.2 Asia-Pacific Persistent Epithelial Defect Management Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Persistent Epithelial Defect Management Market Size by Region (2020-2025)

8.4 Asia-Pacific Persistent Epithelial Defect Management Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Persistent Epithelial Defect Management Market Size (2020-2031)

9.2 Latin America Persistent Epithelial Defect Management Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Persistent Epithelial Defect Management Market Size by Country (2020-2025)

9.4 Latin America Persistent Epithelial Defect Management Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Persistent Epithelial Defect Management Market Size (2020-2031)

10.2 Middle East & Africa Persistent Epithelial Defect Management Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Persistent Epithelial Defect Management Market Size by Country (2020-2025)

10.4 Middle East & Africa Persistent Epithelial Defect Management Market Size by Country (2026-2031)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Dompe Farmaceutici

11.1.1 Dompe Farmaceutici Company Details

11.1.2 Dompe Farmaceutici Business Overview

11.1.3 Dompe Farmaceutici Persistent Epithelial Defect Management Introduction

11.1.4 Dompe Farmaceutici Revenue in Persistent Epithelial Defect Management Business (2020-2025)

11.1.5 Dompe Farmaceutici Recent Development

11.2 OcuNexus Therapeutics

11.2.1 OcuNexus Therapeutics Company Details

11.2.2 OcuNexus Therapeutics Business Overview

11.2.3 OcuNexus Therapeutics Persistent Epithelial Defect Management Introduction

11.2.4 OcuNexus Therapeutics Revenue in Persistent Epithelial Defect Management Business (2020-2025)

11.2.5 OcuNexus Therapeutics Recent Development

11.3 Eyevance Pharmaceuticals

11.3.1 Eyevance Pharmaceuticals Company Details

11.3.2 Eyevance Pharmaceuticals Business Overview

11.3.3 Eyevance Pharmaceuticals Persistent Epithelial Defect Management Introduction

11.3.4 Eyevance Pharmaceuticals Revenue in Persistent Epithelial Defect Management Business (2020-2025)

11.3.5 Eyevance Pharmaceuticals Recent Development

11.4 Noveome Biotherapeutics

11.4.1 Noveome Biotherapeutics Company Details

11.4.2 Noveome Biotherapeutics Business Overview

11.4.3 Noveome Biotherapeutics Persistent Epithelial Defect Management Introduction

11.4.4 Noveome Biotherapeutics Revenue in Persistent Epithelial Defect Management Business (2020-2025)

11.4.5 Noveome Biotherapeutics Recent Development

11.5 RegeneRx Biopharmaceuticals

11.5.1 RegeneRx Biopharmaceuticals Company Details

11.5.2 RegeneRx Biopharmaceuticals Business Overview

11.5.3 RegeneRx Biopharmaceuticals Persistent Epithelial Defect Management Introduction

11.5.4 RegeneRx Biopharmaceuticals Revenue in Persistent Epithelial Defect Management Business (2020-2025)

11.5.5 RegeneRx Biopharmaceuticals Recent Development

11.6 Recordati Rare Diseases

11.6.1 Recordati Rare Diseases Company Details

11.6.2 Recordati Rare Diseases Business Overview

11.6.3 Recordati Rare Diseases Persistent Epithelial Defect Management Introduction

11.6.4 Recordati Rare Diseases Revenue in Persistent Epithelial Defect Management Business (2020-2025)

11.6.5 Recordati Rare Diseases Recent Development

11.7 Mimetech

11.7.1 Mimetech Company Details

11.7.2 Mimetech Business Overview

11.7.3 Mimetech Persistent Epithelial Defect Management Introduction

11.7.4 Mimetech Revenue in Persistent Epithelial Defect Management Business (2020-2025)

11.7.5 Mimetech Recent Development

11.8 Johnson & Johnson

11.8.1 Johnson & Johnson Company Details

11.8.2 Johnson & Johnson Business Overview

11.8.3 Johnson & Johnson Persistent Epithelial Defect Management Introduction

11.8.4 Johnson & Johnson Revenue in Persistent Epithelial Defect Management Business (2020-2025)

11.8.5 Johnson & Johnson Recent Development

11.9 Bausch Health

11.9.1 Bausch Health Company Details

11.9.2 Bausch Health Business Overview

11.9.3 Bausch Health Persistent Epithelial Defect Management Introduction

11.9.4 Bausch Health Revenue in Persistent Epithelial Defect Management Business (2020-2025)

11.9.5 Bausch Health Recent Development

11.10 Integra Lifesciences

11.10.1 Integra Lifesciences Company Details

11.10.2 Integra Lifesciences Business Overview

11.10.3 Integra Lifesciences Persistent Epithelial Defect Management Introduction

11.10.4 Integra Lifesciences Revenue in Persistent Epithelial Defect Management Business (2020-2025)

11.10.5 Integra Lifesciences Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Dompe Farmaceutici

Eyevance Pharmaceuticals

RegeneRx Biopharmaceuticals

Recordati Rare Diseases

OcuNexus Therapeutics

Noveome Biotherapeutics

List of Tables

Table 1. Global Persistent Epithelial Defect Management Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Medication

Table 3. Key Players of Physical Therapy

Table 4. Key Players of Surgery

Table 5. Key Players of Other

Table 6. Global Persistent Epithelial Defect Management Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Persistent Epithelial Defect Management Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global Persistent Epithelial Defect Management Market Size by Region (2020-2025) & (US$ Million)

Table 9. Global Persistent Epithelial Defect Management Market Share by Region (2020-2025)

Table 10. Global Persistent Epithelial Defect Management Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 11. Global Persistent Epithelial Defect Management Market Share by Region (2026-2031)

Table 12. Persistent Epithelial Defect Management Market Trends

Table 13. Persistent Epithelial Defect Management Market Drivers

Table 14. Persistent Epithelial Defect Management Market Challenges

Table 15. Persistent Epithelial Defect Management Market Restraints

Table 16. Global Persistent Epithelial Defect Management Revenue by Players (2020-2025) & (US$ Million)

Table 17. Global Persistent Epithelial Defect Management Market Share by Players (2020-2025)

Table 18. Global Top Persistent Epithelial Defect Management Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Persistent Epithelial Defect Management as of 2024)

Table 19. Ranking of Global Top Persistent Epithelial Defect Management Companies by Revenue (US$ Million) in 2024

Table 20. Global 5 Largest Players Market Share by Persistent Epithelial Defect Management Revenue (CR5 and HHI) & (2020-2025)

Table 21. Global Key Players of Persistent Epithelial Defect Management, Headquarters and Area Served

Table 22. Global Key Players of Persistent Epithelial Defect Management, Product and Application

Table 23. Global Key Players of Persistent Epithelial Defect Management, Date of Enter into This Industry

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Persistent Epithelial Defect Management Market Size by Type (2020-2025) & (US$ Million)

Table 26. Global Persistent Epithelial Defect Management Revenue Market Share by Type (2020-2025)

Table 27. Global Persistent Epithelial Defect Management Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 28. Global Persistent Epithelial Defect Management Revenue Market Share by Type (2026-2031)

Table 29. Global Persistent Epithelial Defect Management Market Size by Application (2020-2025) & (US$ Million)

Table 30. Global Persistent Epithelial Defect Management Revenue Market Share by Application (2020-2025)

Table 31. Global Persistent Epithelial Defect Management Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 32. Global Persistent Epithelial Defect Management Revenue Market Share by Application (2026-2031)

Table 33. North America Persistent Epithelial Defect Management Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 34. North America Persistent Epithelial Defect Management Market Size by Country (2020-2025) & (US$ Million)

Table 35. North America Persistent Epithelial Defect Management Market Size by Country (2026-2031) & (US$ Million)

Table 36. Europe Persistent Epithelial Defect Management Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 37. Europe Persistent Epithelial Defect Management Market Size by Country (2020-2025) & (US$ Million)

Table 38. Europe Persistent Epithelial Defect Management Market Size by Country (2026-2031) & (US$ Million)

Table 39. Asia-Pacific Persistent Epithelial Defect Management Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 40. Asia-Pacific Persistent Epithelial Defect Management Market Size by Region (2020-2025) & (US$ Million)

Table 41. Asia-Pacific Persistent Epithelial Defect Management Market Size by Region (2026-2031) & (US$ Million)

Table 42. Latin America Persistent Epithelial Defect Management Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 43. Latin America Persistent Epithelial Defect Management Market Size by Country (2020-2025) & (US$ Million)

Table 44. Latin America Persistent Epithelial Defect Management Market Size by Country (2026-2031) & (US$ Million)

Table 45. Middle East & Africa Persistent Epithelial Defect Management Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 46. Middle East & Africa Persistent Epithelial Defect Management Market Size by Country (2020-2025) & (US$ Million)

Table 47. Middle East & Africa Persistent Epithelial Defect Management Market Size by Country (2026-2031) & (US$ Million)

Table 48. Dompe Farmaceutici Company Details

Table 49. Dompe Farmaceutici Business Overview

Table 50. Dompe Farmaceutici Persistent Epithelial Defect Management Product

Table 51. Dompe Farmaceutici Revenue in Persistent Epithelial Defect Management Business (2020-2025) & (US$ Million)

Table 52. Dompe Farmaceutici Recent Development

Table 53. OcuNexus Therapeutics Company Details

Table 54. OcuNexus Therapeutics Business Overview

Table 55. OcuNexus Therapeutics Persistent Epithelial Defect Management Product

Table 56. OcuNexus Therapeutics Revenue in Persistent Epithelial Defect Management Business (2020-2025) & (US$ Million)

Table 57. OcuNexus Therapeutics Recent Development

Table 58. Eyevance Pharmaceuticals Company Details

Table 59. Eyevance Pharmaceuticals Business Overview

Table 60. Eyevance Pharmaceuticals Persistent Epithelial Defect Management Product

Table 61. Eyevance Pharmaceuticals Revenue in Persistent Epithelial Defect Management Business (2020-2025) & (US$ Million)

Table 62. Eyevance Pharmaceuticals Recent Development

Table 63. Noveome Biotherapeutics Company Details

Table 64. Noveome Biotherapeutics Business Overview

Table 65. Noveome Biotherapeutics Persistent Epithelial Defect Management Product

Table 66. Noveome Biotherapeutics Revenue in Persistent Epithelial Defect Management Business (2020-2025) & (US$ Million)

Table 67. Noveome Biotherapeutics Recent Development

Table 68. RegeneRx Biopharmaceuticals Company Details

Table 69. RegeneRx Biopharmaceuticals Business Overview

Table 70. RegeneRx Biopharmaceuticals Persistent Epithelial Defect Management Product

Table 71. RegeneRx Biopharmaceuticals Revenue in Persistent Epithelial Defect Management Business (2020-2025) & (US$ Million)

Table 72. RegeneRx Biopharmaceuticals Recent Development

Table 73. Recordati Rare Diseases Company Details

Table 74. Recordati Rare Diseases Business Overview

Table 75. Recordati Rare Diseases Persistent Epithelial Defect Management Product

Table 76. Recordati Rare Diseases Revenue in Persistent Epithelial Defect Management Business (2020-2025) & (US$ Million)

Table 77. Recordati Rare Diseases Recent Development

Table 78. Mimetech Company Details

Table 79. Mimetech Business Overview

Table 80. Mimetech Persistent Epithelial Defect Management Product

Table 81. Mimetech Revenue in Persistent Epithelial Defect Management Business (2020-2025) & (US$ Million)

Table 82. Mimetech Recent Development

Table 83. Johnson & Johnson Company Details

Table 84. Johnson & Johnson Business Overview

Table 85. Johnson & Johnson Persistent Epithelial Defect Management Product

Table 86. Johnson & Johnson Revenue in Persistent Epithelial Defect Management Business (2020-2025) & (US$ Million)

Table 87. Johnson & Johnson Recent Development

Table 88. Bausch Health Company Details

Table 89. Bausch Health Business Overview

Table 90. Bausch Health Persistent Epithelial Defect Management Product

Table 91. Bausch Health Revenue in Persistent Epithelial Defect Management Business (2020-2025) & (US$ Million)

Table 92. Bausch Health Recent Development

Table 93. Integra Lifesciences Company Details

Table 94. Integra Lifesciences Business Overview

Table 95. Integra Lifesciences Persistent Epithelial Defect Management Product

Table 96. Integra Lifesciences Revenue in Persistent Epithelial Defect Management Business (2020-2025) & (US$ Million)

Table 97. Integra Lifesciences Recent Development

Table 98. Research Programs/Design for This Report

Table 99. Key Data Information from Secondary Sources

Table 100. Key Data Information from Primary Sources

Table 101. Authors List of This Report

List of Figures

Figure 1. Persistent Epithelial Defect Management Picture

Figure 2. Global Persistent Epithelial Defect Management Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Persistent Epithelial Defect Management Market Share by Type: 2024 VS 2031

Figure 4. Medication Features

Figure 5. Physical Therapy Features

Figure 6. Surgery Features

Figure 7. Other Features

Figure 8. Global Persistent Epithelial Defect Management Market Size by Application (2020-2031) & (US$ Million)

Figure 9. Global Persistent Epithelial Defect Management Market Share by Application: 2024 VS 2031

Figure 10. Epithelial/Limbal Case Studies

Figure 11. Inflammatory Disease Case Studies

Figure 12. Neurotrophic Disease Case Studies

Figure 13. Others Case Studies

Figure 14. Persistent Epithelial Defect Management Report Years Considered

Figure 15. Global Persistent Epithelial Defect Management Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 16. Global Persistent Epithelial Defect Management Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 17. Global Persistent Epithelial Defect Management Market Share by Region: 2024 VS 2031

Figure 18. Global Persistent Epithelial Defect Management Market Share by Players in 2024

Figure 19. Global Persistent Epithelial Defect Management Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 20. The Top 10 and 5 Players Market Share by Persistent Epithelial Defect Management Revenue in 2024

Figure 21. North America Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. North America Persistent Epithelial Defect Management Market Share by Country (2020-2031)

Figure 23. United States Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Canada Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Europe Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Europe Persistent Epithelial Defect Management Market Share by Country (2020-2031)

Figure 27. Germany Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. France Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. U.K. Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Italy Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Russia Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Ireland Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Asia-Pacific Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Asia-Pacific Persistent Epithelial Defect Management Market Share by Region (2020-2031)

Figure 35. China Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Japan Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. South Korea Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Southeast Asia Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. India Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Australia & New Zealand Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Latin America Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Latin America Persistent Epithelial Defect Management Market Share by Country (2020-2031)

Figure 43. Mexico Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Brazil Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Middle East & Africa Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Middle East & Africa Persistent Epithelial Defect Management Market Share by Country (2020-2031)

Figure 47. Israel Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Saudi Arabia Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. UAE Persistent Epithelial Defect Management Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. Dompe Farmaceutici Revenue Growth Rate in Persistent Epithelial Defect Management Business (2020-2025)

Figure 51. OcuNexus Therapeutics Revenue Growth Rate in Persistent Epithelial Defect Management Business (2020-2025)

Figure 52. Eyevance Pharmaceuticals Revenue Growth Rate in Persistent Epithelial Defect Management Business (2020-2025)

Figure 53. Noveome Biotherapeutics Revenue Growth Rate in Persistent Epithelial Defect Management Business (2020-2025)

Figure 54. RegeneRx Biopharmaceuticals Revenue Growth Rate in Persistent Epithelial Defect Management Business (2020-2025)

Figure 55. Recordati Rare Diseases Revenue Growth Rate in Persistent Epithelial Defect Management Business (2020-2025)

Figure 56. Mimetech Revenue Growth Rate in Persistent Epithelial Defect Management Business (2020-2025)

Figure 57. Johnson & Johnson Revenue Growth Rate in Persistent Epithelial Defect Management Business (2020-2025)

Figure 58. Bausch Health Revenue Growth Rate in Persistent Epithelial Defect Management Business (2020-2025)

Figure 59. Integra Lifesciences Revenue Growth Rate in Persistent Epithelial Defect Management Business (2020-2025)

Figure 60. Bottom-up and Top-down Approaches for This Report

Figure 61. Data Triangulation

Figure 62. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-2O19977

Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Intelligent Elderly Care Equipment Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-3E8132

Wed Sep 17 00:00:00 UTC 2025

Add to Cart

Global Radiation Monitoring Systems Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-23I7304

Tue Sep 16 00:00:00 UTC 2025

Add to Cart

Global Ophthalmology Homeopathic Products Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-8T5982

Tue Sep 16 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global Persistent Epithelial Defect Management Market Research Report 2025

Published Date: September 2025

Report Code: QYRE-Auto-2O19977

Global Persistent Epithelial Defect Management Market Research Report 2025

FEATURED COMPANIES

Persistent Epithelial Defect Management Market Size

Persistent Epithelial Defect Management Market

Scope of Persistent Epithelial Defect Management Market Report

Chapter Outline

FAQ for this report

How fast is Persistent Epithelial Defect Management Market growing?

What is the Persistent Epithelial Defect Management Market size in 2031?

Who are the main players in the Persistent Epithelial Defect Management Market report?

What are the Application segmentation covered in the Persistent Epithelial Defect Management Market report?

What are the Type segmentation covered in the Persistent Epithelial Defect Management Market report?

FEATURED COMPANIES

RELATED REPORTS